摘要
目的探讨腺病毒早期2区结合因子1(adenovirus early region 2 binding factor 1,E2F1)在子宫内膜癌中的表达及与临床病理特征和错配修复蛋白(mismatch repair proteins,MMR)之间相关性。方法采用实时定量PCR(RT-qPCR)法检测67例子宫内膜癌组织及癌旁组织的E2F1表达量,免疫组化SP法测定子宫内膜癌组织中4种MMR蛋白的表达,分析其相关性。结果E2F1在子宫内膜癌组织中的mRNA表达量(1.62±1.20)明显高于癌旁组织(0.37±0.31),差异有统计学意义(P<0.001)。且E2F1高表达组与低表达组在肌层浸润深度、淋巴结转移及脉管间质浸润中,差异有统计学意义(P<0.01),但在病理类型、临床分期、神经侵犯中,差异无统计学意义(P>0.05)。MMR蛋白缺失组较MMR表达正常组E2F1表达量更高(P<0.001)。结论E2F1在子宫内膜癌中高表达,且可能与MMR之间存在一定相互作用,从而影响子宫内膜癌患者的预后。
Objective To investigate the expression of adenovirus early region 2 binding factor 1(E2F1)in endometrial carcinoma(EC)and its correlation with clinicopathological features,as well as the correlation between E2F1 and the expression of mismatch repair proteins(MMR).Methods E2F1 expression was detected by RT-qPCR in the tissues of 67 cases of endometrial carcinoma and para-carcinoma tissues and the expression of four MMR proteins in the endometrial carcinoma tissues was detected by immunohistochemistry.expression of four MMR proteins in endometrial carcinoma tissues by immunohistochemistry.Results The mRNA expression of E2F1 in endometrial cancer tissues(1.62±1.20)was significantly higher than that in para-carcinoma tissues(0.37±0.31),and the difference was statistically significant(P<0.001).There were significant differences in the depth of myometrial invasion,lymph node metastasis and lymphovascular space invasion(LVSI)in the high E2F1 expression group compared with the low expression group(P<0.01),but there was no significant in pathological type,clinical staging,and neurological invasion(P>0.05).dMMR group had a higher expression of E2F1 than that in the pMMR group(P<0.001).Conclusions E2F1 is highly expressed in endometrial cancer,which may have some interaction with MMR,thus affecting the prognosis of endometrial cancer patients.
作者
陈舒月
冯文
CHEN Shuyue;FENG Wen(Department of Gynecology,Lianyungang Hospital,Xuzhou Medical University,Jiangsu 222000,China)
出处
《中国妇产科临床杂志》
CSCD
北大核心
2024年第2期109-112,共4页
Chinese Journal of Clinical Obstetrics and Gynecology
基金
连云港市妇幼健康科研项目(F202005)。